» Articles » PMID: 21034421

Multifunctional Nanomedicine Platform for Cancer Specific Delivery of SiRNA by Superparamagnetic Iron Oxide Nanoparticles-dendrimer Complexes

Overview
Journal Curr Drug Deliv
Specialty Pharmacology
Date 2010 Nov 2
PMID 21034421
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of Superparamagnetic Iron Oxide (SPIO) nanoparticles and Poly(Propyleneimine) generation 5 dendrimers (PPI G5) to cooperatively provoke siRNA complexation was investigated in order to develop a targeted, multifunctional siRNA delivery system for cancer therapy. Poly(ethylene glycol) (PEG) coating and cancer specific targeting moiety (LHRH peptide) have been incorporated into SPIO-PPI G5-siRNA complexes to enhance serum stability and selective internalization by cancer cells. Such a modification of siRNA nanoparticles enhanced its internalization into cancer cells and increased the efficiency of targeted gene suppression in vitro. Moreover, the developed siRNA delivery system was capable of sufficiently enhancing in vivo antitumor activity of an anticancer drug (Cisplatin). The proposed approach demonstrates potential for the creation of targeted multifunctional nanomedicine platforms with the ability to deliver therapeutic siRNA specifically to cancer cells in order to prevent severe adverse side effects on healthy tissues and in situ monitoring of the therapeutic outcome using clinically relevant imaging techniques.

Citing Articles

What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible....

Szupryczynski K, Czelen P, Jelinski T, Szefler B Int J Nanomedicine. 2024; 19:9503-9547.

PMID: 39296940 PMC: 11410046. DOI: 10.2147/IJN.S469217.


Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.

Garbuzenko O, Sapiezynski J, Girda E, Rodriguez-Rodriguez L, Minko T Small. 2024; 20(41):e2307462.

PMID: 38342698 PMC: 11316847. DOI: 10.1002/smll.202307462.


Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach.

Fadaka A, Akinsoji T, Klein A, Madiehe A, Meyer M, Keyster M J Pharm Anal. 2024; 13(11):1235-1251.

PMID: 38174117 PMC: 10759263. DOI: 10.1016/j.jpha.2023.07.008.


Sorafenib-Based Drug Delivery Systems: Applications and Perspectives.

Wang L, Chen M, Ran X, Tang H, Cao D Polymers (Basel). 2023; 15(12).

PMID: 37376284 PMC: 10303456. DOI: 10.3390/polym15122638.


Oral delivery of RNAi for cancer therapy.

Afrin H, Bai R, Kumar R, Ahmad S, Agarwal S, Nurunnabi M Cancer Metastasis Rev. 2023; 42(3):699-724.

PMID: 36971908 PMC: 10040933. DOI: 10.1007/s10555-023-10099-x.